Adaptyv Bio
Switzerland - EpalingesBiotechnology
Focus: Adaptyv Bio is a Swiss-based next-gen protein foundry leveraging AI and automation to design and manufacture novel protein therapeutics, positioned at the intersection of computational biology and lab automation. The company is publicly listed and actively scaling operations across biology, supply chain, and IT functions.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
34+3 this month
Stable — net +3 jobs in 30d
37 added, 34 removed. Backfill posture.
Should You Work at Adaptyv Bio?
AI assessmentHigh-upside, high-risk early-stage bet best suited for technologists and operators comfortable with platform risk and the 3-5 year runway before clinical validation.
Why Work Here
- Founding-stage opportunity in AI-driven drug discovery with recent $40M Series A (Aug 2026) and public market access, signaling capital runway and investor confidence.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Adaptyv Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.